RE:Almylam article.. Wish we could pick up the pace Imtesty, thanks for sharing. That would be amazing if the RNAi approach for reducing PCSK9 proceeds well through its Phase II and III trials. In their Phase I trial, they were able to maintain LDL-C reductions 140 days after the single injection as opposed to the 26X per year for the PCSK9 monoclonal antibody approaches. And before anyone asks (since it always seems to come up) this has zero relevance to Resverlogix RVX-208 because RVX-208 doesn't affect LDL. It is instead related to statins and statin alternatives.